Taysha Gene Therapies (NASDAQ:TSHA) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Taysha Gene Therapies (NASDAQ:TSHA) announced its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02), Zacks reports.

Here are the key takeaways from Taysha Gene Therapies’ conference call:

• TSHA-102 demonstrated encouraging durability and breadth of benefit in REVEAL Part A: the response rate rose from 75% at three months to 100% at 12 months among 12 patients, with 310 functional gains reported across multiple Rett syndrome domains.
• Taysha completed dosing in the over-enrolled REVEAL pivotal trial with 17 patients and in the ASPIRE trial with four young children. The company expects to report six-month REVEAL interim data and FDA feedback on the potential BLA pathway in the first half of 2027, which could accelerate submission relative to waiting for 12-month data.
• A patient in the REVEAL pivotal trial experienced a moderate, treatment-related peripheral sensory neuropathy approximately six weeks after dosing and was briefly hospitalized. Taysha said the patient recovered substantially, characterized the event as a known AAV9-associated risk, and reported no severe treatment-related serious adverse events or dose-limiting toxicities among 33 treated patients.
• The company expanded its Catalent partnership for commercial manufacturing, with process performance qualification activities underway and the BLA-enabling campaign expected to be completed in the fourth quarter of 2026. Taysha said the FDA has found clinical and commercial lots analytically comparable to date, potentially allowing Part A data to support the regulatory submission.
• Taysha ended the quarter with $455.4 million in cash and cash equivalents, including $230 million in gross follow-on financing proceeds, and expects its resources to fund planned operations into the second half of 2028 and through potential BLA approval.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $6.68 on Wednesday. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a twelve month low of $2.69 and a twelve month high of $7.30. The company has a fifty day moving average of $6.08 and a 200-day moving average of $5.47. The firm has a market capitalization of $1.92 billion, a P/E ratio of -17.58 and a beta of 1.22.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TSHA. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Citizens Jmp restated a “market outperform” rating and set a $11.00 price target on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Robert W. Baird upped their price target on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and an average price target of $12.77.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the transaction, the insider owned 936,410 shares in the company, valued at $5,843,198.40. This trade represents a 17.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its position in Taysha Gene Therapies by 143.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares during the last quarter. Guggenheim Capital LLC purchased a new position in shares of Taysha Gene Therapies during the 4th quarter valued at about $61,000. Panagora Asset Management Inc. bought a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $64,000. CIBC Asset Management Inc bought a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $66,000. Finally, Marex Group plc purchased a new stake in Taysha Gene Therapies in the second quarter worth approximately $29,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.